Status: Not yet recruiting

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure

Participants needed: 500

Trial details

Phase: Phase 2, Phase 3Age: 10-80Biological sex: AllType: InterventionalSponsor: Ebima Clifford OkundayeUpdated: Feb 18, 2026Locations: 1

Eligibility criteria

Hospitalized patients [+3]

Status: Not yet recruiting

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.

Participants needed: 3,000

Trial details

Phase: Phase 2, Phase 3Age: 18-90Biological sex: AllType: InterventionalSponsor: Ebima Clifford OkundayeUpdated: Sep 8, 2025Locations: 1

Eligibility criteria

Inclusion criteria [+6]

Symptomatic renal failure [+3]

Clinical trials

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression